EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors

Cian M Ohlendieck iD, Carlos Matellan, Cristina Bauset, Bella Raphael, Mary Nwaezeigwe, Emer Flynn, Kevin Okamoto, Desmond Winter, Colm Collins iD, Katie Doogan iD, Seán T Martin, Glen Doherty and 2 more

The Journal of Physiology · 2026-07-28

DOI: 10.1113/jp290658 ↗

At a glance

Journal article in The Journal of Physiology, published online on 2026-07-28. Written by Cian M Ohlendieck and 13 co-authors. Institution: Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland. 59 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIDDK NIH HHS, Science Foundation Ireland, Irish Research Council for Science, Engineering and Technology.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

Fibroblasts have emerged as inflammatory entities in ulcerative colitis (UC) and eosinophilic oesophagitis, positioning these cells as attractive therapeutic targets. Previous studies have shown that hydroxylase inhibitors elicit anti‐inflammatory responses, but their effects on fibroblasts during inflammation remain unknown. Here we test the effects of hydroxylase inhibitors on TNFSF14/LIGHT‐driven inflammation in intestinal and oesophageal fibroblasts. Human endoscopic biopsies were obtained from paired inflamed or non‐inflamed areas of active UC patients. Primary human colonic and oesophageal fibroblasts from healthy donors were pre‐treated with hydroxylase inhibitors and/or treated with LIGHT. Flow cytometry, qRT‐PCR, enzyme‐linked immunosorbent assays, immunoblotting, immunofluorescence and RNAseq were used. LIGHT induced inflammatory responses in intestinal fibroblasts predominantly via lymphotoxin β receptor (LTβR), which was more highly expressed than herpes virus entry mediator in UC biopsies and colonic fibroblasts. A comparative analysis of the response to LIGHT between colonic and oesophageal fibroblasts revealed unique transcriptional profiles and a shared inflammatory gene programme. Pretreatment with hydroxylase inhibitors had a selective inhibitory effect on the expression of several LIGHT‐mediated inflammatory factors in colonic and oesophageal fibroblasts. Mechanistic studies revealed differential molecular targets as LIGHT‐driven non‐canonical nuclear factor‐κB activity was targeted by hydroxylase inhibitors in oesophageal but unaffected in colonic fibroblasts. While dimethyloxalylglycine (DMOG) abrogated LIGHT‐induced p38 phosphorylation in colonic fibroblasts, p38 inhibitors did not phenocopy the anti‐inflammatory effects of DMOG. In summary, we established a previously unrecognised LIGHT/LTβR‐driven inflammatory response in intestinal fibroblasts and characterised differential effects and pathways for LIGHT signalling in intestinal and oesophageal fibroblasts. We identified therapeutic effects of hydroxylase inhibitors via targeting of distinct pathways in these cells. image Key points LIGHT induces partially conserved inflammatory responses in colonic and oesophageal fibroblasts. Hydroxylase inhibitors selectively diminish LIGHT‐mediated inflammation in both types of fibroblasts. Dimethyloxalylglycine reduces accumulation of the non‐canonical nuclear factor‐κB member p52 in oesophageal fibroblasts. The mechanism whereby hydroxylase inhibitors reduce LIGHT‐mediated inflammation in colonic fibroblasts remains to be elucidated.

Subjects

Author keywords

eosinophilic esophagitis and hydroxylase inhibitorsfibroblastsinflammationinflammatory bowel disease

Authors and institutions

  • Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland.
  • School of Biomolecular and Biomedical Sciences, University College Dublin, Belfield, Dublin, Ireland.
  • School of Medicine, University College Dublin, Belfield, Dublin, Ireland.
  • Centre for Colorectal Disease, St Vincent's University Hospital and School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland.
  • Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California, USA.
  • Rady Children's Hospital, San Diego, California, USA.

ORCID profiles: Cian M Ohlendieck, Colm Collins, Katie Doogan, Mario C Manresa

Funding

  • NIDDK NIH HHS
  • Science Foundation Ireland
  • Irish Research Council for Science, Engineering and Technology
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Ohlendieck, C. M., Matellan, C., Bauset, C., Raphael, B., Nwaezeigwe, M., Flynn, E., Okamoto, K., Winter, D., Collins, C., Doogan, K., Martin, S. T., Doherty, G., Aceves, S. S., & Manresa, M. C. (2026). TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors. The Journal of Physiology. https://doi.org/10.1113/jp290658

Vancouver

Ohlendieck CM, Matellan C, Bauset C, Raphael B, Nwaezeigwe M, Flynn E, et al. TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors. The Journal of Physiology. 2026. doi:10.1113/jp290658

BibTeX
@article{Ohlendieck2026,
  author = {Ohlendieck, Cian M and Matellan, Carlos and Bauset, Cristina and Raphael, Bella and Nwaezeigwe, Mary and Flynn, Emer and Okamoto, Kevin and Winter, Desmond and Collins, Colm and Doogan, Katie and Martin, Seán T and Doherty, Glen and Aceves, Seema S and Manresa, Mario C},
  title = {TNFSF14/LIGHT responses in intestinal and oesophageal fibroblasts are differentially modulated by hydroxylase inhibitors},
  journal = {The Journal of Physiology},
  year = {2026},
  doi = {10.1113/jp290658}
}
Start for free →